Trials / Completed
CompletedNCT02953678
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 71 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to assess the efficacy of ruxolitinib in combination with corticosteroids in subjects with Grades II to IV steroid-refractory acute graft-versus-host disease (GVHD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ruxolitinib | |
| DRUG | Prednisone or methylprednisolone | Either oral prednisone or IV methylprednisolone may be used to begin corticosteroid treatment at the investigator's discretion. |
Timeline
- Start date
- 2016-12-30
- Primary completion
- 2018-01-31
- Completion
- 2019-08-14
- First posted
- 2016-11-03
- Last updated
- 2021-11-24
- Results posted
- 2019-08-20
Locations
38 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02953678. Inclusion in this directory is not an endorsement.